P700: TREATMENT-FREE REMISSION (TFR) AFTER DASATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR): FINAL 5-YEAR RESULTS OF DASFREE. (23rd June 2022) - Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Saussele, S.; Rea, D.; Mahon, F.-X.; Levy, M. Y.; Gómez-Casares, M. T.; Mauro, M. J.; Sy, O.; Martin-Regueira, P.; Lipton, J. H.